1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Oral Rehydration Solution (ORS) Market
4. Market Overview
4.1. Introduction
4.1.1. Product Sales Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, 2017–2031
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Raw material and Pricing trends
5.2. Regulatory Scenario by Region/globally
5.3. COVID-19 Impact Analysis
5.4. ORS campaigns by global institutions/NGOs
6. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, By Product Sales
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product Sales, 2017–2031
6.3.1. OTC Products
6.3.2. Prescription
6.4. Market Attractiveness Analysis, By Product Sales
7. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, By Dosage Form
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Dosage Form, 2017–2031
7.3.1. Powder
7.3.2. Liquid
7.3.3. Tablet
7.4. Market Attractiveness Analysis, By Dosage Form
8. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, By Customer Age
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Customer Age, 2017–2031
8.3.1. Children
8.3.2. Adult
8.4. Market Attractiveness Analysis, By Customer Age
9. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, By Indication
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Indication, 2017–2031
9.3.1. Diarrhea
9.3.2. Gastroenteritis
9.3.3. Electrolyte Imbalance
9.3.4. Others
9.4. Market Attractiveness Analysis, By Indication
10. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, By Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness Analysis, By Distribution Channel
11. Global Oral Rehydration Solution (ORS) Market Analysis and Forecast, By Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, By Region
12. North America Oral Rehydration Solution (ORS) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Sales, 2017–2031
12.2.1. OTC Products
12.2.2. Prescription
12.3. Market Value Forecast, by Dosage Form, 2017–2031
12.3.1. Powder
12.3.2. Liquid
12.3.3. Tablet
12.4. Market Value Forecast, by Customer Age, 2017–2031
12.4.1. Children
12.4.2. Adult
12.5. Market Value Forecast, by Indication, 2017–2031
12.5.1. Diarrhea
12.5.2. Gastroenteritis
12.5.3. Electrolyte Imbalance
12.5.4. Others
12.6. Market Value Forecast, by Distribution Channel, 2017–2031
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Value Forecast, by Country, 2017–2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Product Sales
12.8.2. By Dosage Form
12.8.3. By Customer Age
12.8.4. By Indication
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Oral Rehydration Solution (ORS) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Sales, 2017–2031
13.2.1. OTC Products
13.2.2. Prescription
13.3. Market Value Forecast, by Dosage Form, 2017–2031
13.3.1. Powder
13.3.2. Liquid
13.3.3. Tablet
13.4. Market Value Forecast, by Customer Age, 2017–2031
13.4.1. Children
13.4.2. Adult
13.5. Market Value Forecast, by Indication, 2017–2031
13.5.1. Diarrhea
13.5.2. Gastroenteritis
13.5.3. Electrolyte Imbalance
13.5.4. Others
13.6. Market Value Forecast, by Distribution Channel, 2017–2031
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Value Forecast, by Country/Sub-region, 2017–2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Product Sales
13.8.2. By Dosage Form
13.8.3. By Customer Age
13.8.4. By Indication
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Oral Rehydration Solution (ORS) Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Sales, 2017–2031
14.2.1. OTC Products
14.2.2. Prescription
14.3. Market Value Forecast, by Dosage Form, 2017–2031
14.3.1. Powder
14.3.2. Liquid
14.3.3. Tablet
14.4. Market Value Forecast, by Customer Age, 2017–2031
14.4.1. Children
14.4.2. Adult
14.5. Market Value Forecast, by Indication, 2017–2031
14.5.1. Diarrhea
14.5.2. Gastroenteritis
14.5.3. Electrolyte Imbalance
14.5.4. Others
14.6. Market Value Forecast, by Distribution Channel, 2017–2031
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Value Forecast, by Country/Sub-region, 2017–2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Product Sales
14.8.2. By Dosage Form
14.8.3. By Customer Age
14.8.4. By Indication
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Oral Rehydration Solution (ORS) Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product Sales, 2017–2031
15.2.1. OTC Products
15.2.2. Prescription
15.3. Market Value Forecast, by Dosage Form, 2017–2031
15.3.1. Powder
15.3.2. Liquid
15.3.3. Tablet
15.4. Market Value Forecast, by Customer Age, 2017–2031
15.4.1. Children
15.4.2. Adult
15.5. Market Value Forecast, by Indication, 2017–2031
15.5.1. Diarrhea
15.5.2. Gastroenteritis
15.5.3. Electrolyte Imbalance
15.5.4. Others
15.6. Market Value Forecast, by Distribution Channel, 2017–2031
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Pharmacies
15.7. Market Value Forecast, by Country/Sub-region, 2017–2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Product Sales
15.8.2. By Dosage Form
15.8.3. By Customer Age
15.8.4. By Indication
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Oral Rehydration Solution (ORS) Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Product Sales, 2017–2031
16.2.1. OTC Products
16.2.2. Prescription
16.3. Market Value Forecast, by Dosage Form, 2017–2031
16.3.1. Powder
16.3.2. Liquid
16.3.3. Tablet
16.4. Market Value Forecast, by Customer Age, 2017–2031
16.4.1. Children
16.4.2. Adult
16.5. Market Value Forecast, by Indication, 2017–2031
16.5.1. Diarrhea
16.5.2. Gastroenteritis
16.5.3. Electrolyte Imbalance
16.5.4. Others
16.6. Market Value Forecast, by Distribution Channel, 2017–2031
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Pharmacies
16.7. Market Value Forecast, by Country/Sub-region, 2017–2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Product Sales
16.8.2. By Dosage Form
16.8.3. By Customer Age
16.8.4. By Indication
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis, by Company, 2021
17.3. Company Profiles
17.3.1. FDC Limited
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. SWOT Analysis
17.3.1.4. Strategic Overview
17.3.2. Cipla
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. SWOT Analysis
17.3.2.4. Strategic Overview
17.3.3. Wallace Pharmaceuticals
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. SWOT Analysis
17.3.3.4. Strategic Overview
17.3.4. Zydus Cadila Healthcare Ltd.
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. SWOT Analysis
17.3.4.4. Strategic Overview
17.3.5. Shereya Life Sciences
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. SWOT Analysis
17.3.5.4. Strategic Overview
17.3.6. Mankind Pharma
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. SWOT Analysis
17.3.6.4. Strategic Overview
17.3.7. Intas Pharmaceuticals Ltd.
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. SWOT Analysis
17.3.7.4. Strategic Overview
17.3.8. Sun Pharma
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. SWOT Analysis
17.3.8.4. Strategic Overview
17.3.9. Dr Reddy’s
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. SWOT Analysis
17.3.9.4. Strategic Overview
17.3.10. Alkem
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. SWOT Analysis
17.3.10.4. Strategic Overview
17.3.11. Lupin
17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.11.2. Product Portfolio
17.3.11.3. SWOT Analysis
17.3.11.4. Strategic Overview
17.3.12. Cadila
17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.12.2. Product Portfolio
17.3.12.3. SWOT Analysis
17.3.12.4. Strategic Overview
17.3.13. RPG Life Sciences
17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.13.2. Product Portfolio
17.3.13.3. SWOT Analysis
17.3.13.4. Strategic Overview
17.3.14. Casca remedies Pvt. Ltd.
17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.14.2. Product Portfolio
17.3.14.3. SWOT Analysis
17.3.14.4. Strategic Overview
17.3.15. Halewood Laboratories Pvt. Ltd.
17.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.15.2. Product Portfolio
17.3.15.3. SWOT Analysis
17.3.15.4. Strategic Overview
17.3.16. Liquid I.V.
17.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.16.2. Product Portfolio
17.3.16.3. SWOT Analysis
17.3.16.4. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/